CRSPCRISPR Therapeutics AG

CSNasdaq (XNAS)·USD

Identity

Security key: 13804
Ticker: CRSP
Type: CS — Common Stock
Exchange: Nasdaq(XNAS)
Venue group: NASDAQ
Operating MIC: XNAS
Market: stocks
Locale: us
Currency: USD
Listed: 2016-10-19
Round lot: 100
Active: Yes
Last seen in a load: 2026-08-14 20:49
Vendor updated: 2026-08-13 06:09
Ticker root / suffix: CRSP

Detail

Enriched 2026-08-14 20:47

Market cap: $5,220,436,335.47
Shares outstanding (class): 96,692,653
Shares outstanding (weighted): 96,692,653
SIC: 2836 BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees: 393
Location: ZUG
Homepage: https://www.crisprtx.com
Description: Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Market cap and share counts drift.

Funds holding this security

130 funds · 130 positions · $702.67M reported value, as of 2026-03-31

All holders →

Fund	Ticker	Position value	% of fund	Balance	Match
iShares Russell 2000 ETF iShares Trust	IWM	$106.06M	0.15%	2,229,658 NS	TICKER
New Perspective Fund New Perspective Fund	—	$92.48M	0.06%	1,944,073 NS	TICKER
State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST	XBI	$80.72M	1.09%	1,696,801 NS	TICKER
SMALLCAP World Fund Inc SMALLCAP World Fund Inc	—	$78.39M	0.10%	1,647,885 NS	TICKER
VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS	VXF	$51.01M	0.06%	1,072,377 NS	TICKER
T. Rowe Price Mid-Cap Growth Fund, Inc. T. ROWE PRICE MID-CAP GROWTH FUND, INC.	—	$49.99M	0.22%	1,050,900 NS	TICKER
iShares Russell 2000 Value ETF iShares Trust	IWN	$37.25M	0.30%	783,058 NS	TICKER
iShares Biotechnology ETF iShares Trust	IBB	$31.57M	0.39%	663,733 NS	TICKER
T. Rowe Price Small-Cap Value Fund, Inc. T. ROWE PRICE SMALL-CAP VALUE FUND, INC.	—	$18.83M	0.20%	395,868 NS	TICKER
Growth Fund AMERICAN FUNDS INSURANCE SERIES	—	$15.92M	0.03%	334,619 NS	TICKER
American Beacon ARK Transformational Innovation… AMERICAN BEACON FUNDS	—	$9.71M	6.19%	204,216 NS	TICKER
JNL/T. Rowe Price Mid-Cap Growth Fund JNL Series Trust	—	$9.02M	0.22%	189,561 NS	TICKER
JNL/Loomis Sayles Global Growth Fund JNL Series Trust	—	$8.71M	1.12%	183,146 NS	TICKER
Master Small Cap Index Series Quantitative Master Series LLC	—	$7.06M	0.15%	148,425 NS	TICKER
T. Rowe Price Institutional Mid-Cap Equity Grow… T. Rowe Price Equity Funds, Inc.	—	$6.11M	0.22%	128,361 NS	TICKER

How positions resolve to the securities master. FIGI_COMPOSITE is exact identifier equality — both sides got the FIGI from Bloomberg. TICKER is a narrow fallback used only where the master row carries no FIGI at all (2,389 rows do not, disproportionately Irish-domiciled US listings like LIN and ACN). Roughly 22% of all positions resolve to the master.

This match is a candidate, not a mapping. N-PORT tickers are filer-entered free text and collide with delisted and foreign symbols. Only 13% of positions carry a ticker at all. Good enough to ask which funds report holding a symbol; not good enough to build exposure reporting on. Prefer the ISIN-resolved link, which is marked FIGI_COMPOSITE.

Funds holding this security

Identifiers

master.security_identifier

TICKERCRSP
CIK0001674416
ISINCH0334081137
Resolved through OpenFIGI from a holdings ISIN, not supplied by the securities vendor.

Identifiers

Classification

classification.v_security_classification

Asset class: Equity
Sector: Health Care
Industry: Biotechnology
Source: LLMunreviewed
Self-reported confidence: 0.95
Model: deepseek
Rationale: CRISPR Therapeutics is a biopharmaceutical company developing gene-based therapies, fitting the biotechnology industry under healthcare.

Classifications are unreviewed model output. All 5,771 assignments carry source = LLM and is_reviewed = false. Confidence is the model’s own estimate and is not calibrated — it clustered at 0.90–0.98 across the whole first pass, including rows that later proved wrong. Use it to order a review queue, not as a probability. Two share classes of one issuer can disagree.

Classification

Fund data

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.